ルベル・インターナショナル病院
| トルコ | オーストリア | スペイン | |
| 肺がんに対するターゲット療法 | から $5,000 | - | から $3,431 |
Bookimedは肺がんに対するターゲット療法価格に追加料金を加算しません。料金はクリニックの公式価格表から来ています。到着時にクリニックで肺がんに対するターゲット療法代を直接お支払いいただきます。
Bookimedはお客様の安全に取り組んでいます。肺がんに対するターゲット療法で高い国際基準を維持し、世界中の国際患者サービスに必要なライセンスを有する医療機関とのみ協力しています。
Bookimedは無料専門サポートを提供します。専属医療コーディネーターが治療前、治療中、治療後にサポートし、あらゆる問題を解決します。肺がんに対するターゲット療法の旅路でお一人になることはありません。
Dr. Carlos Vergés Roger is a prize-winning ophthalmologist at Dexeus University Hospital in Barcelona. He won the National Research Prize for his groundbreaking study on tear secretion. This work became the foundation for modern dry eye syndrome treatment. Dr. Vergés Roger holds a PhD from Harvard University.
スペインでは、肺がんの標的療法を開始する前に、バイオマーカー検査が臨床的に必須となっている。すべての患者に義務付けられているわけではないが、スペイン医薬品医療機器庁（AEMPS）などの保健当局は、特定の標的薬の承認および処方のために、これらの検査を義務付けている。
Bookimed専門家の見解：スペインの腫瘍センターでは、バイオマーカー検査と3テスラMRIなどの高度な診断技術を統合していることがよくあります。ナバラ大学クリニックなどの施設は、欧州臨床腫瘍学会（ESMO）の認定を受けています。これにより、検査プロトコルが最新の国際的な精密医療基準に準拠し、より迅速な結果が得られます。遺伝子検査の結果を待ってから治療を開始する患者は、長期的な病状の安定性が向上することが多いため、この統合は非常に重要です。
患者の意見：患者は、遺伝子検査は個別化医療への明確な道筋を示す、絶対に欠かせないステップであると強調しています。多くの患者は、標準的な化学療法に同意する前に、医療チームに検査結果を明確に求めることを推奨しています。
Targeted lung cancer therapies in Spain utilize precision medicine to treat specific genetic mutations like EGFR, ALK, and ROS1. Leading oncology centers provide advanced inhibitors including Osimertinib and Selpercatinib, alongside innovative clinical trials for KRAS G12C and MYC mutations at JCI-accredited facilities.
Bookimed Expert Insight: Spain presents a unique research-heavy landscape where patients access tomorrow's drugs today. Centers like Hospital Ruber Internacional and Navarra prioritize early-phase trials for MYC inhibitors like OMO-103. This clinical trial focus often bypasses standard reimbursement delays seen in the public sector.
Patient Consensus: Accuracy in initial genetic testing is the most critical step for success. Patients emphasize discussing drug resistance early and pursuing clinical trial options for the newest inhibitors.
You can participate in clinical trials for targeted therapy in Spain, which is a global leader in oncological research. Patients access cutting-edge biomarker-driven treatments and Phase 1 trials, including innovative lung cancer vaccines like BNT116, at JCI-accredited centers in Madrid, Barcelona, and Pamplona.
Bookimed Expert Insight: Spain is one of only 7 global sites for the BNT116 lung cancer vaccine trial. Clinics like Clinica Universidad de Navarra offer high-level integration between research and care. This allows patients with rare mutations to access Phase 1 experimental treatments long before they reach the general market.
Patient Consensus: Patients emphasize that early biomarker testing is vital. Many suggest looking beyond standard care into Phase 1 trials if you have specific resistance patterns or rare lung cancer mutations.
Spains National Health System (SNS) provides universal coverage for targeted therapies that are approved by the Ministry of Health. Patients access these treatments through public hospitals, where tax-funded care is free at delivery, though regional variations in availability and pharmaceutical co-payments may apply.
Bookimed Expert Insight: While public coverage is universal, private centers like Clinica Universidad de Navarra or Hospital Ruber Internacional offer faster access to trials. Data shows these JCI-accredited facilities often implement digital imaging and molecular labs for specialized lung cancer care earlier than public regional centers.
Patient Consensus: Navigating health bureaucracy is easier when contacting patient associations for support. Most confirm that once a drug is on the national list, costs become negligible for low-income families.
Spain hosts world-class oncology centers like Clinica Universidad de Navarra and Hospital Ruber Internacional, specializing in targeted lung cancer therapy. These Joint Commission International-accredited facilities offer advanced treatments including CyberKnife, immunotherapy, and molecular medicine within highly integrated research-led networks.
Bookimed Expert Insight: Spain’s oncology strength lies in research integration rather than single-center dominance. Clinics like Navarra maintain Joint Commission International status while serving 140,000 patients annually. This high volume ensures surgeons maintain precision in robotic and molecular treatments. Patients should target Madrid for the concentrated expertise found at Forbes-ranked institutions.
Patient Consensus: Patients value the speed of Spanish diagnostics for suspected lung cancer. Many recommend starting private treatment for immediate access, then transitioning to public care for long-term medication coverage.